The small GTP-binding protein Rho plays an important role in several cellular functions. RhoA, which is a member of the Rho family, initiates cellular processes that act on its direct downstream effector Rho-associated kinase (ROCK). ROCK inhibition protects against dopaminergic cell death induced by dopaminergic neurotoxins. It has been suggested that ROCK inhibition activates neuroprotective survival cascades in dopaminergic neurons. Axon-stabilizing effects in damaged neurons may represent another mechanism of neuroprotection of dopaminergic neurons by ROCK inhibition. However, it has been shown that microglial cells play a crucial role in neuroprotection by ROCK inhibition and that activation of microglial ROCK mediates major components of the microglial inflammatory response. Additional mechanisms such as interaction with autophagy may also contribute to the neuroprotective effects of ROCK inhibition. Interestingly, ROCK interacts with several brain factors that play a major role in dopaminergic neuron vulnerability such as NADPH-oxidase, angiotensin, and estrogen. ROCK inhibition may provide a new neuroprotective strategy for Parkinson’s disease. This is of particular interest because ROCK inhibitors are currently used against vascular diseases in clinical practice. However, it is necessary to develop more potent and selective ROCK inhibitors to reduce side effects and enhance the efficacy.
AguileraMOBeronWColomboMI. 2012. The actin cytoskeleton participates in the early events of autophagosome formation upon starvation induced autophagy. Autophagy8:1590–603.
2.
Alves da CostaCCheclerF. 2011. Apoptosis in Parkinson’s disease: is p53 the missing link between genetic and sporadic Parkinsonism?Cell Signal23:963–8.
3.
AmanoMItoMKimuraKFukataYChiharaKNakanoT, and others. 1996. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem271:20246–9.
4.
AmanoMNakayamaMKaibuchiK. 2010. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 67:545–54.
5.
AminEDubeyBNZhangSCGremerLDvorskyRMollJM, and others. 2013. Rho-kinase: regulation, (dys)function, and inhibition. Biol Chem394:1399–410.
6.
BabiorBM. 1999. NADPH oxidase: an update. Blood93:1464–76.
BanBKJunMHRyuHHJangDJAhmadSTLeeJA. 2013. Autophagy negatively regulates early axon growth in cortical neurons. Mol Cell Biol33:3907–19.
9.
BarciaCBautistaVSanchez-BahilloAFernandez-VillalbaEFaucheuxBPozayPozaM, and others. 2005. Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm112:1237–48.
10.
BarciaCRosCMAnneseVCarrillo-de SauvageMARos-BernalFGomezA, and others. 2012. ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Sci Rep2:809.
11.
BauerPONukinaN. 2009. Enhanced degradation of mutant huntingtin by rho kinase inhibition is mediated through activation of proteasome and macroautophagy. Autophagy5:747–8.
12.
BauerPOWongHKOyamaFGoswamiAOkunoMKinoY, and others. 2009. Inhibition of Rho kinases enhances the degradation of mutant huntingtin. J Biol Chem284:13153–64.
13.
BenigniACornaDZojaCSonzogniALatiniRSalioM, and others. 2009. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest119:524–30.
14.
BergerZRavikumarBMenziesFMOrozLGUnderwoodBRPangalosMN, and others. 2006. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet15:433–42.
15.
BermelCTongesLPlanchampVGillardonFWeishauptJHDietzGP, and others. 2009. Combined inhibition of Cdk5 and ROCK additively increase cell survival, but not the regenerative response in regenerating retinal ganglion cells. Mol Cell Neurosci42:427–37.
16.
BernhartEKollroserMRechbergerGReicherHHeinemannASchratlP, and others. 2010. Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture. Proteomics10:141–58.
17.
BinaméFSakryDDimouLJolivelVTrotterJ. 2013. NG2 regulates directional migration of oligodendrocyte precursor cells via Rho GTPases and polarity complex proteins. J Neurosci33:10858–74.
18.
BokuSNakagawaSTodaHKatoATakamuraNOmiyaY, and others. 2013. ROCK2 regulates bFGF-induced proliferation of SH-SY5Y cells through GSK-3beta and beta-catenin pathway. Brain Res1492:7–17.
19.
BorisoffJFChanCCHiebertGWOschipokLRobertsonGSZamboniR, and others. 2003. Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates. Mol Cell Neurosci22:405–16.
20.
BorrajoARodriguez-PerezAIDiaz-RuizCGuerraMJLabandeira-GarciaJL. 2014a. Microglial TNF-alpha mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia62:145–57.
21.
BorrajoARodriguez-PerezAIVillar-ChedaBGuerraMJLabandeira-GarciaJL. 2014b. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death. Neuropharmacology85C:1–8.
22.
BowermanMMurrayLMBoyerJGAndersonCLKotharyR. 2012. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med10:24.
23.
BrendelAFelzenVMoraweTMantheyDBehlC. 2013. Differential regulation of apoptosis-associated genes by estrogen receptor alpha in human neuroblastoma cells. Restor Neurol Neurosci31:199–211.
24.
BreslinJWSunHXuWRodarteCMoyABWuMH, and others. 2006. Involvement of ROCK-mediated endothelial tension development in neutrophil-stimulated micro-vascular leakage. Am J Physiol Heart Circ Physiol290:H741–50.
25.
BrochardVCombadiereBPrigentALaouarYPerrinABeray-BerthatV, and others. 2009. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegenera-tion in a mouse model of Parkinson disease. J Clin Invest119:182–92.
26.
BryanBADennstedtEMitchellDCWalsheTENomaKLoureiroR, and others. 2010. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J24:3186–95.
27.
BudzynKMarleyPDSobeyCG. 2006. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci27:97–104.
28.
BurkeREO’MalleyK. 2013. Axon degeneration in Parkinson’s disease. Exp Neurol246:72–83.
29.
CamposFLCristovaoACRochaSMFonsecaCPBaltazarG. 2012. GDNF contributes to oestrogen-mediated protection of midbrain dopaminergic neurones. J Neuro-endocrinol24:1386–97.
30.
CarbajalJMGratrixMLYuCHSchaefferRCJr.2000. ROCK mediates thrombin’s endothelial barrier dysfunction. Am J Physiol Cell Physiol279:C195–204.
31.
CassisPContiSRemuzziGBenigniA. 2010. Angiotensin receptors as determinants of life span. Pflugers Arch459:325–32.
32.
CrewsLSpencerBDesplatsPPatrickCPaulinoARockensteinE, and others. 2010. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One5:e9313.
33.
CuervoAMStefanisLFredenburgRLansburyPTSulzerD. 2004. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science305:1292–5.
34.
ChanCCWongAKLiuJSteevesJDTetzlaffW. 2007. ROCK inhibition with Y27632 activates astrocytes and increases their expression of neurite growth-inhibitory chondroitin sulfate proteoglycans. Glia55:369–84.
35.
ChenMLiuQLiuATanMXieZUriA, and others. 2014. Simply combining fasudil and lipoic acid in a novel multitargeted chemical entity potentially useful in central nervous system disorders. RSC Adv4: 37266–9.
36.
ChenMLiuAOuyangYHuangYChaoXPiR. 2013. Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders?Expert Opin Investig Drugs22:537–50.
37.
ChenSCLiuCCHuangSYChiouSJ. 2011. Vascular hyperpermeability in response to inflammatory mustard oil is mediated by Rho kinase in mice systemically exposed to arsenic. Microvasc Res82:182–9.
38.
ChengHCKimSROoTFKarevaTYaryginaORzhetskayaM, and others. 2011. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J Neurosci31:2125–35.
39.
ChuYMorfiniGALanghamerLBHeYBradySTKordowerJH. 2012. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease. Brain135:2058–73.
40.
ChungYCKoHWBokEParkESHuhSHNamJH, and others. 2010. The role of neuroinflammation on the pathogenesis of Parkinson’s disease. BMB Rep43:225–32.
41.
DasASmithJAGibsonCVarmaAKRaySKBanikNL. 2011. Estrogen receptor agonists and estrogen attenuate TNF-alpha-induced apoptosis in VSC4.1 motoneurons. J Endocrinol208:171–82.
42.
de CavanaghEMInserraFFerderL. 2011. Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria? Cardiovasc Res89:31–40.
43.
DehayBBoveJRodriguez-MuelaNPerierCRecasensABoyaP, and others. 2010. Pathogenic lysosomal depletion in Parkinson’s disease. J Neurosci30:12535–44.
44.
DingJLiQYWangXSunCHLuCZXiaoBG. 2010. Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial inflammatory responses in mice. J Neurochem114:1619–29.
45.
DingJYuJZLiQYWangXLuCZXiaoBG. 2009. Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF. Brain Behav Immun23:1083–8.
46.
DukaTDukaVJoyceJNSidhuA. 2009. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson’s disease models. FASEB J23:2820–30.
GalloG. 2004. Myosin II activity is required for severing-induced axon retraction in vitro. Exp Neurol189:112–21.
49.
GaoHMHongJSZhangWLiuB. 2002. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci22:782–90.
50.
GaoHMLiuBZhangWHongJS. 2003. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease. FASEB J17:1954–6.
51.
Garrido-GilPValenzuelaRVillar-ChedaBLanciegoJLLabandeira-GarciaJL. 2013. Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin-angiotensin system in the nigra. Brain Struct Funct218:373–88.
52.
GavardJGutkindJS. 2008. Protein kinase C-related kinase and ROCK are required for thrombin-induced endothelial cell permeability downstream from Galpha12/13 and Galpha11/q. J Biol Chem283:29888–96.
53.
GerhardAPaveseNHottonGTurkheimerFEsMHammersA, and others. 2006. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis21:404–12.
54.
GoldmanSM. 2014. Environmental toxins and Parkinson’s disease. Annu Rev Pharmacol Toxicol54:141–64.
55.
GollapudiLOblingerMM. 2001. Estrogen effects on neurite outgrowth and cytoskeletal gene expression in ERalpha-transfected PC12 cell lines. Exp Neurol171:308–16.
56.
Gonzalez-HernandezTCruz-MurosIAfonso-OramasDSalas-HernandezJCastro-HernandezJ. 2010. Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease. Front Neuroanat4:140.
57.
GrammasPMartinezJMillerB. 2011. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med13:e19.
58.
GrammatopoulosTNJonesSMAhmadiFAHooverBRSnellLDSkochJ, and others. 2007. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener2:1.
59.
GreenwoodJWaltersCEPryceGKanugaNBeraudEBakerD, and others. 2003. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J17:905–7.
60.
HamanoTYenSHGendronTKoLWKuriyamaM. 2012. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging33:2306–20.
61.
HeHYimMLiuKHCodySCShulkesABaldwinGS. 2008. Involvement of G proteins of the Rho family in the regulation of Bcl-2-like protein expression and caspase 3 activation by Gastrins. Cell Signal20:83–93.
62.
HeasmanSJRidleyAJ. 2010. Multiple roles for RhoA during T cell transendothelial migration. Small GTPases1:174–79.
63.
Hernandez-BaltazarDMendoza-GarridoMEMartinez-FongD. 2013. Activation of GSK-3beta and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS One8:e70951.
64.
HerskowitzJHFengYMattheysesALHalesCMHigginbothamLADuongDM, and others. 2013. Pharmacologic inhibition of ROCK2 suppresses amyloid-beta production in an Alzheimer’s disease mouse model. J Neurosci33:19086–98.
65.
HigashiMShimokawaHHattoriTHirokiJMukaiYMorikawaK, and others. 2003. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res93:767–75.
66.
HippenstielSSchmeckBN’GuessanPDSeyboldJKrullMPreissnerK, and others. 2002. Rho protein inactivation induced apoptosis of cultured human endothelial cells. Am J Physiol Lung Cell Mol Physiol283:L830–8.
67.
HirokiJShimokawaHHigashiMMorikawaKKandabashiTKawamuraN, and others. 2004. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol37:537–46.
68.
HirschECVyasSHunotS. 2012. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord18(Suppl 1):S210–2.
69.
HobanDBConnaughtonEConnaughtonCHoganGThorntonCMulcahyP, and others. 2013. Further characterisation of the LPS model of Parkinson’s disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain Behav Immun27:91–100.
70.
HöltjeMHoffmannAHofmannFMuckeCGrosseGVan RooijenN, and others. 2005. Role of Rho GTPase in astrocyte morphology and migratory response during in vitro wound healing. J Neurochem95:1237–48.
71.
HoningHvan den BergTKvan der PolSMDijkstraCDvan der KammenRACollardJG, and others. 2004. RhoA activation promotes transendothelial migration of monocytes via ROCK. J Leukoc Biol75:523–8.
72.
IidaHIidaMTakenakaMFukuokaNDohiS. 2008. Rho-kinase inhibitor and nicotinamide adenine dinucleotide phosphate oxidase inhibitor prevent impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking in rats. J Renin Angiotensin Aldosterone Syst9:89–94.
73.
IkedaHNagashimaKYanaseMTomiyaTAraiMInoueY, and others. 2003. Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol285:G880–6.
74.
Jackson-LewisVJakowecMBurkeREPrzedborskiS. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration4:257–69.
75.
JellingerKA. 2013. The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations. Int Rev Neurobiol110:1–47.
76.
JoglarBRodriguez-PallaresJRodriguez-PerezAIReyPGuerraMJLabandeira-GarciaJL. 2009. The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem109:656–69.
KochJCTongesLBarskiEMichelUBahrMLingorP. 2014. ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS. Cell Death Dis5:e1225.
79.
Labandeira-GarciaJLRodriguez-PallaresJDominguez-MeijideAValenzuelaRVillar-ChedaBRodriguez-PerezAI. 2013. Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson’s disease. Mov Disord28:1337–42.
80.
Labandeira-GarciaJLRodriguez-PallaresJRodriguez-PerezAIGarrido-GilPVillar-ChedaBValenzuelaR, and others. 2012. Brain angiotensin and dopaminergic degeneration: relevance to Parkinson’s disease. Am J Neurodegener Dis1:226–44.
81.
LaflammeLGasparoMGalloJMPayetMDGallo-PayetN. 1996. Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J Biol Chem271:22729–35.
82.
LanzTVDingZHoPPLuoJAgrawalANSrinageshH, and others. 2010. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest120:2782–94.
83.
LauCLO’SheaRDBrobergBVBischofLBeartPM. 2011. The Rho kinase inhibitor Fasudil up-regulates astrocytic glutamate transport subsequent to actin remodelling in murine cultured astrocytes. Br J Pharmacol163:533–45.
84.
LehmannMFournierASelles-NavarroIDerghamPSebokALeclercN, and others. 1999. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J Neurosci19:7537–47.
85.
LevyOAMalageladaCGreeneLA. 2009. Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis14:478–500.
86.
LiMZhuanLWangTRaoKYangJYangJ, and others. 2012. Apocynin improves erectile function in diabetic rats through regulation of NADPH oxidase expression. J Sex Med9:3041–50.
87.
LindqvistDHallSSurovaYNielsenHMJanelidzeSBrundinL, and others. 2013. Cerebrospinal fluid inflammatory markers in Parkinson’s disease—associations with depression, fatigue, and cognitive impairment. Brain Behav Immun33:183–9.
88.
LingorPTeuschNSchwarzKMuellerRMackHBahrM, and others. 2007. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem103:181–9.
89.
Lopez-MartinECarunchoHJRodriguez-PallaresJGuerraMJLabandeira-GarciaJL. 1999. Striatal dopaminergic afferents concentrate in GDNF-positive patches during development and in developing intrastriatal striatal grafts. J Comp Neurol406:199–206.
90.
LuciusRGallinatSRosenstielPHerdegenTSieversJUngerT. 1998. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med188:661–70.
91.
MalageladaCJinZHGreeneLA. 2008. RTP801 is induced in Parkinson’s disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci28:14363–71.
92.
MarchesiCParadisPSchiffrinEL. 2008. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci29:367–74.
93.
MattsonMPMaudsleyS. 2009. Live longer sans the AT1A receptor. Cell Metab9:403–5.
94.
MeffertSStollMSteckelingsUMBottariSPUngerT. 1996. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol122:59–67.
95.
MehtaPKGriendlingKK. 2007. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol292:C82–97.
96.
Mendez-AlvarezESoto-OteroRHermida-AmeijeirasALopez-RealAMLabandeira-GarciaJL. 2002. Effects of aluminum and zinc on the oxidative stress caused by 6-hydroxydopamine autoxidation: relevance for the pathogenesis of Parkinson’s disease. Biochim Biophys Acta1586:155–68.
97.
MérotYFerriereFGailhousteLHuetGPercevaultFSaligautC, and others. 2009. Different outcomes of unliganded and liganded estrogen receptor-alpha on neurite outgrowth in PC12 cells. Endocrinology150:200–11.
98.
MinLJMogiMIwaiMHoriuchiM. 2009. Signaling mechanisms of angiotensin II in regulating vascular senescence. Ageing Res Rev8:113–21.
99.
MoonMYKimHJLiYKimJGJeonYJWonHY, and others. 2013. Involvement of small GTPase RhoA in the regulation of superoxide production in BV2 cells in response to fibrillar Abeta peptides. Cell Signal25:1861–9.
100.
MoraleMCSerraPAL’EpiscopoFTiroloCCanigliaSTestaN, and others. 2006. Estrogen, neuroinflammation and neuroprotection in Parkinson’s disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience138:869–78.
101.
Morales-GarciaJASusinCAlonso-GilSPerezDIPalomoVPerezC, and others. 2013. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci4:350–60.
102.
MuellerBKMackHTeuschN. 2005. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov4:387–98.
103.
MuñozAGarrido-GilPDominguez-MeijideALabandeira-GarciaJL. 2014. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson’s disease. Involvement of vascular endothelial growth factor and interleukin-1beta. Exp Neurol261C:720–32.
104.
NakagawaOFujisawaKIshizakiTSaitoYNakaoKNarumiyaS. 1996. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett392:189–93.
105.
NomaKKiharaYHigashiY. 2012. Striking crosstalk of ROCK signaling with endothelial function. J Cardiol60:1–6.
106.
OhtsuHSuzukiHNakashimaHDhobaleSFrankGDMotleyED, and others. 2006. Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension48:534–40.
107.
OlanowCW. 2007. The pathogenesis of cell death in Parkinson’s disease–2007. Mov Disord22(Suppl 17):S335–42.
108.
OlsonMF. 2008. Applications for ROCK kinase inhibition. Curr Opin Cell Biol20:242–8.
109.
OsterSRadadKSchellerDHesseMBalanzewWReichmannHGilleG. 2014. Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture. Eur J Pharmacol724:31-42.
110.
OuchiYYoshikawaESekineYFutatsubashiMKannoTOgusuT, and others. 2005. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol57:168–75.
111.
PaintliaASPaintliaMKSinghAKSinghI. 2013. Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-alpha-dependent mechanism. Glia61:1500–17.
112.
PanPShenMYuHLiYLiDHouT. 2013. Advances in the development of Rho-associated protein kinase (ROCK) inhibitors. Drug Discov Today18:1323–33.
113.
PopatRAVan Den EedenSKTannerCMMcGuireVBernsteinALBlochDA, and others. 2005. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology65:383–90.
114.
QinLLiuYWangTWeiSJBlockMLWilsonB, and others. 2004. NADPH oxidase mediates lipopoly-saccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem279:1415–21.
115.
RagonesePD’AmelioMCallariGSalemiGMorganteLSavettieriG. 2006a. Age at menopause predicts age at onset of Parkinson’s disease. Mov Disord21:2211–4.
116.
RagonesePD’AmelioMSavettieriG. 2006b. Implications for estrogens in Parkinson’s disease: an epidemiological approach. Ann N Y Acad Sci1089:373–82.
ReRN. 2004. Tissue renin angiotensin systems. Med Clin North Am88:19–38.
119.
ReineckeKLuciusRReineckeARickertUHerdegenTUngerT. 2003. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J17:2094–6.
RiesVHenchcliffeCKarevaTRzhetskayaMBlandRDuringMJ, and others. 2006. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson’s disease. Proc Natl Acad Sci U S A103:18757–62.
122.
Rodriguez-PallaresJPargaJAMunozAReyPGuerraMJLabandeira-GarciaJL. 2007. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem103:145–56.
123.
Rodriguez-PallaresJQuirozCRPargaJAGuerraMJLabandeira-GarciaJL. 2004. Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur J Neurosci20:1489–98.
124.
Rodriguez-PallaresJReyPPargaJAMunozAGuerraMJLabandeira-GarciaJL. 2008. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis31:58–73.
125.
Rodriguez-PerezAIDominguez-MeijideALanciegoJLGuerraMJLabandeira-GarciaJL. 2013. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson’s disease. Neurobiol Dis58:209–19.
126.
Rodriguez-PerezAIValenzuelaRJoglarBGarrido-GilPGuerraMJLabandeira-GarciaJL. 2011. Renin angiotensin system and gender differences in dopaminergic degeneration. Mol Neurodegener6:58.
127.
Rodriguez-PerezAIValenzuelaRVillar-ChedaBGuerraMJLabandeira-GarciaJL. 2012. Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system. Brain135:124–38.
128.
Rodriguez-PerezAIValenzuelaRVillar-ChedaBGuerraMJLanciegoJLLabandeira-GarciaJL. 2010. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson’s disease. Exp Neurol224:517–26.
129.
SaavedraJM. 2005. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol25:485–512.
130.
Sanchez-IglesiasSMendez-AlvarezEIglesias-GonzalezJMunoz-PatinoASanchez-SelleroILabandeira-GarciaJL, and others. 2009. Brain oxidative stress and selective behaviour of aluminium in specific areas of rat brain: potential effects in a 6-OHDA-induced model of Parkinson’s disease. J Neurochem109:879–88.
131.
SheikhAMNagaiARyuJKMcLarnonJGKimSUMasudaJ. 2009. Lysophosphatidylcholine induces glial cell activation: role of rho kinase. Glia57:898–907.
132.
ShiJWeiL. 2007. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp (Warsz)55:61–75.
133.
ShulmanLM. 2002. Is there a connection between estrogen and Parkinson’s disease?Parkinsonism Relat Disord8:289–95.
134.
StegbauerJLeeDHSeubertSEllrichmannGManzelAKvakanH, and others. 2009. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A106:14942–7.
135.
SunHBreslinJWZhuJYuanSYWuMH. 2006. Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation13:237–47.
136.
SuzukiSBrownCMDela CruzCDYangEBridwellDAWisePM. 2007. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc Natl Acad Sci U S A104:6013–8.
137.
TollesonCMFangJY. 2013. Advances in the mechanisms of Parkinson’s disease. Discov Med15:61–6.
138.
TöngesLFrankTTatenhorstLSaalKAKochJCSzegoEM, and others. 2012. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease. Brain135:3355–70.
139.
TöngesLGuntherRSuhrMJansenJBalckASaalKA, and others. 2014. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia62:217–32.
140.
TripanichkulWSripanichkulchaiKFinkelsteinDI. 2006. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. Brain Res1084:28–37.
141.
ValenzuelaRBarroso-ChineaPVillar-ChedaBJoglarBMunozALanciegoJL, and others. 2010. Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death. J Neuropathol Exp Neurol69:1130–42.
142.
VegetoEBenedusiVMaggiA. 2008. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol29:507–19.
143.
Villar-ChedaBDominguez-MeijideAJoglarBRodriguez-PerezAIGuerraMJLabandeira-GarciaJL. 2012. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis47:268–79.
144.
WadaKAraiHTakanashiMFukaeJOizumiHYasudaT, and others. 2006. Expression levels of vascular endothelial growth factor and its receptors in Parkinson’s disease. Neuroreport17:705–9.
145.
WakitaSIzumiYNakaiTAdachiKTakada-TakatoriYKumeT, and others. 2014. Staurosporine induces dopaminergic neurite outgrowth through AMP-activated protein kinase/mammalian target of rapamycin signaling pathway. Neuropharmacology77:39–48.
146.
WaltersCEPryceGHankeyDJSebtiSMHamiltonADBakerD, and others. 2002. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J Immunol168:4087–94.
147.
WangSCaoCChenZBankaitisVTzimaESheibaniN, and others. 2012. Pericytes regulate vascular basement membrane remodeling and govern neutrophil extravasation during inflammation. PLoS One7:e45499.
148.
WuDCTeismannPTieuKVilaMJackson-LewisVIschiropoulosH, and others. 2003. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci U S A100:6145–50.
149.
YanJZhouXGuoJJMaoLWangYJSunJ, and others. 2012. Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in vitro. J Neurochem120:721–31.
150.
YangYColemanMZhangLZhengXYueZ. 2013. Autophagy in axonal and dendritic degeneration. Trends Neurosci36:418–28.
151.
YangYFukuiKKoikeTZhengX. 2007. Induction of autophagy in neurite degeneration of mouse superior cervical ganglion neurons. Eur J Neurosci26:2979–88.
152.
YasudaTFukuda-TaniMNihiraTWadaKHattoriNMizunoY, and others. 2007. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson’s disease. Exp Neurol206:308–17.
153.
YasuharaTShingoTKobayashiKTakeuchiAYanoAMuraokaK, and others. 2004. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson’s disease. Eur J Neurosci19:1494–504.
154.
YasuharaTShingoTMuraokaKWen JiYKamedaMTakeuchiA, and others. 2005. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson’s disease model. Brain Res1038:1–10.
155.
YuLHuangJZhaiDLiuLGuoKLongX, and others. 2014. MAPT rs242562 and GSK3B rs334558 are associated with Parkinson’s disease in central China. BMC Neurosci15:54.
156.
ZhangHLiYYuJGuoMMengJLiuC, and others. 2013. Rho kinase inhibitor fasudil regulates microglia polarization and function. Neuroimmunomodulation20:313–22.
157.
ZhangYGuXYuanX. 2007. Phenylalanine activates the mitochondria-mediated apoptosis through the RhoA/Rho-associated kinase pathway in cortical neurons. Eur J Neurosci25:1341–8.
158.
ZhangZFauserUSchluesenerHJ. 2008. Dexamethasone suppresses infiltration of RhoA+ cells into early lesions of rat traumatic brain injury. Acta Neuropathol115:335–43.
159.
ZhouZKimJInsoleraRPengXFinkDJMataM. 2011. Rho GTPase regulation of alpha-synuclein and VMAT2: implications for pathogenesis of Parkinson’s disease. Mol Cell Neurosci48:29–37.
